ReShape Lifesciences Inc
NASDAQ:RSLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ReShape Lifesciences Inc
Operating Income
ReShape Lifesciences Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Operating Income
-$6.3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Operating Income
$4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
35%
|
CAGR 10-Years
16%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Operating Income
$1.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Operating Income
$5.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Operating Income
$8.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Operating Income
$3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
23%
|
CAGR 10-Years
15%
|
|
ReShape Lifesciences Inc
Glance View
ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 47 full-time employees. The company went IPO on 2016-10-06. The firm is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The firm's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.
See Also
What is ReShape Lifesciences Inc's Operating Income?
Operating Income
-6.3m
USD
Based on the financial report for Mar 31, 2025, ReShape Lifesciences Inc's Operating Income amounts to -6.3m USD.
What is ReShape Lifesciences Inc's Operating Income growth rate?
Operating Income CAGR 5Y
21%
Over the last year, the Operating Income growth was 47%. The average annual Operating Income growth rates for ReShape Lifesciences Inc have been 54% over the past three years , 21% over the past five years .
